.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Novartis
Daiichi Sankyo
Covington
Medtronic
Julphar
Mallinckrodt
Dow
Teva
Merck

Generated: June 29, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,637,461

« Back to Dashboard

Details for Patent: 5,637,461

Title: Ligands of HIV-1 TAT protein
Abstract:Methods are described for the identification of nucleic acid ligand solutions to the HIV-1 tat protein. Motifs I, II and III are nucleic acid ligands identified by the disclosed methods.
Inventor(s): Gold; Larry M. (Boulder, CO), Tuerk; Craig (Boulder, CO)
Assignee: NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Filing Date:Mar 24, 1995
Application Number:08/409,439
Claims:1. A method for identifying non-naturally occurring single-stranded nucleic acid ligands to the HIV-1 tat protein comprising:

a) preparing a candidate mixture comprising non-naturally occurring single-stranded nucleic acids;

b) contacting said candidate mixture with the HIV-1 tat protein, wherein non-naturally occurring single-stranded nucleic acids having an increased affinity to the HIV-1 tat protein relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

c) partitioning said increased affinity non-naturally occurring single-stranded nucleic acids from the remainder of the candidate mixture; and

d) amplifying said increased affinity non-naturally occurring single-stranded nucleic acids to yield a mixture of non-naturally occurring single-stranded nucleic acids enriched in non-naturally occurring single-stranded nucleic acids having increased affinity to the HIV-1 tat protein, whereby non-naturally occurring single-stranded nucleic acid ligands to the HIV-1 tat protein are identified.

2. The method of claim 1 further comprising e) repeating steps b), c)and d).

3. The method of claim 1 wherein said candidate mixture of non-naturally occurring single-stranded nucleic acids contacted with the HIV-1 tat protein is comprised of RNA.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Queensland Health
Argus Health
US Department of Justice
Medtronic
Fish and Richardson
McKinsey
Daiichi Sankyo
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot